Biotech News
Related news
MNKDMannKind2026-05-27 20:00 EST
MannKind to Present at Jefferies Global Healthcare Conference
MNKDMannKind2026-09-02 12:30 EST
MannKind to Present at Upcoming Investor Conferences
ALTAltimmune2026-09-03 12:00 EST
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
MLYSMineralys Therapeutics2026-08-26 12:00 EST
Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
MLYSMineralys Therapeutics2026-06-08 20:05 EST
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
BLTEBelite Bio2026-06-02 12:00 EST
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
ALGSAligos Therapeutics2026-09-02 12:00 EST
Aligos Therapeutics to Present at the Cantor Global Healthcare Conference
SGMTSagimet Biosciences2026-08-04 11:00 EST
Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
LXRXLexicon Pharmaceuticals2026-05-28 12:30 EST
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
CVRXCVRx2026-05-27 20:30 EST
CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
MannKind
Inhaled Drug Delivery MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery. Commercial Portfolio Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid...
Recent company news
MNKDMannKind2026-10-14 20:01 EST
MannKind to Participate in the Chardan Healthcare Conference
MNKDMannKind2026-10-10 00:00 EST
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)
MNKDMannKind2026-09-09 10:30 EST
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
MNKDMannKind2026-09-09 10:30 EST
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
MNKDMannKind2026-09-02 12:30 EST
MannKind to Present at Upcoming Investor Conferences
Stock data
- Close
- 3.05 USD
- Market cap
- 1.06B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States